Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children

  • Walsh T
  • Driscoll T
  • Milligan P
 et al. 
  • 47

    Readers

    Mendeley users who have this article in their library.
  • 68

    Citations

    Citations of this article.

Abstract

The pharmacokinetics of voriconazole in children receiving 4 mg/kg intravenously (i.v.) demonstrate substantially lower plasma exposures (as defined by area under the concentration-time curve [AUC]) than those in adults receiving the same therapeutic dosage. These differences in pharmacokinetics between children and adults limit accurate prediction of pediatric voriconazole exposure based on adult dosages. We therefore studied the pharmacokinetics and tolerability of higher dosages of an i.v.-to-oral regimen of voriconazole in immunocompromised children aged 2 to

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Thomas J. Walsh

  • Timothy Driscoll

  • Peter A. Milligan

  • Nolan D. Wood

  • Haran Schlamm

  • Andreas H. Groll

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free